Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib, or With Atezolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

• Status: Not yet recruiting
• Trial end date: 2026-09-01

Summary

This is an investigator-initiated industry-supported phase I clinical trial conducted in the phase I clinic, MD Anderson Cancer Center. The study consists of two parts: dose finding (MTD (maximum tolerated dose) determination) and dose expansion parts.

The safety and tolerability of TTF in combination with cabozantinib (cohort 1) or with nab-paclitaxel and atezolizumab (cohort 2) in patients with advanced solid tumors involving the abdomen or thorax will be evaluated. Patients with HCC and renal carcinoma will be included in cohort 1 and treated with TTF (150 kHz frequency for HCC and 200 kHz for renal cell carcinoma) in combination with cabozantinib. Patients with breast cancer and gynecologic tumors (ovarian/fallopian, endometrial/primary peritoneal tumors) will be included in cohort 2 and treated with TTF (150 kHz frequency for breast cancer and 200 kHz for gynecologic tumors) with nab-paclitaxel and atezolizumab.

• Phase: Phase 1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Treatments: Albumin-Bound Paclitaxel; Atezolizumab; Paclitaxel